LFG
CRSP icon

Larson Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Larson Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.2K Buy
1,433
+95
+7% +$5.01K ﹤0.01% 1316
2026
Q1 		$63.6K Buy
1,338
+456
+52% +$24.1K ﹤0.01% 1225
2025
Q4 		$46.3K Buy
882
+639
+263% +$38.3K ﹤0.01% 1269
2025
Q3 		$15.7K Sell
243
-67
-22% -$3.85K ﹤0.01% 1775
2025
Q2 		$15.1K Sell
310
-1
-0.3% -$39 ﹤0.01% 1622
2025
Q1 		$10.6K Sell
311
-159
-34% -$6.74K ﹤0.01% 1614
2024
Q4 		$18.5K Sell
470
-14
-3% -$661 ﹤0.01% 1248
2024
Q3 		$22.7K Sell
484
-81
-14% -$4.11K ﹤0.01% 1152
2024
Q2 		$30.5K Buy
565
+276
+96% +$16K ﹤0.01% 937
2024
Q1 		$19.7K Buy
289
+20
+7% +$1.43K ﹤0.01% 892
2023
Q4 		$16.8K Hold
269
– – ﹤0.01% 896
2023
Q3 		$12.2K Sell
269
-30
-10% -$1.55K ﹤0.01% 943
2023
Q2 		$16.8K Hold
299
– – ﹤0.01% 789
2023
Q1 		$13.5K Sell
299
-15
-5% -$729 ﹤0.01% 837
2022
Q4 		$12.8K Sell
314
-100
-24% -$5.3K ﹤0.01% 790
2022
Q3 		$27K Hold
414
– – ﹤0.01% 562
2022
Q2 		$25K Hold
414
– – ﹤0.01% 501
2022
Q1 		$26K Sell
414
-8
-2% -$502 ﹤0.01% 484
2021
Q4 		$32K Buy
422
+151
+56% +$13.2K 0.01% 460
2021
Q3 		$30K Buy
271
+167
+161% +$21K 0.01% 379
2021
Q2 		$17K Hold
104
– – ﹤0.01% 463
2021
Q1 		$13K Buy
104
+15
+17% +$2.27K ﹤0.01% 486
2020
Q4 		$14K Buy
89
+60
+207% +$7.09K ﹤0.01% 433
2020
Q3 		$2K Hold
29
– – ﹤0.01% 589
2020
Q2 		$2K Hold
29
– – ﹤0.01% 548
2020
Q1 		$1K Buy
+29
New +$1.5K ﹤0.01% 462

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Larson Financial Group's CRSP Position: Q2 2026 in Review

Larson Financial Group increased its CRISPR Therapeutics (CRSP) stake by 7.1% in Q2 2026, buying an estimated $5.01K and bringing the position to 1,433 shares worth $78.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1316.

Larson Financial Group first reported a position in CRSP in Q1 2020 and has held it in 26 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Larson Financial Group held 1,433 shares of CRISPR Therapeutics worth $78.2K as of Q2 2026.
  • Larson Financial Group bought 95 CRISPR Therapeutics shares in Q2 2026, an estimated $5.01K.
  • CRISPR Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1316 holding.
  • Larson Financial Group first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.